Calithera Biosciences (NASDAQ:CALA)‘s stock had its “outperform” rating restated by Leerink Swann in a report issued on Friday.
Other research analysts have also issued research reports about the company. Zacks Investment Research lowered Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. ValuEngine lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 18th. Finally, Citigroup upgraded Calithera Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $6.95 to $14.00 in a research report on Friday, February 16th. Three research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $18.00.
NASDAQ:CALA opened at $5.45 on Friday. Calithera Biosciences has a 12-month low of $5.35 and a 12-month high of $20.05. The company has a market cap of $209.48, a P/E ratio of -6.49 and a beta of 2.62.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.09). Calithera Biosciences had a negative net margin of 107.21% and a negative return on equity of 17.49%. The company had revenue of $7.24 million for the quarter, compared to analyst estimates of $7.28 million. During the same quarter in the prior year, the firm earned ($0.45) EPS. equities analysts forecast that Calithera Biosciences will post -1.21 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in CALA. Jane Street Group LLC acquired a new position in Calithera Biosciences during the 4th quarter valued at approximately $103,000. Lazard Asset Management LLC acquired a new position in Calithera Biosciences during the 4th quarter worth $167,000. Trexquant Investment LP acquired a new position in Calithera Biosciences during the 3rd quarter worth $168,000. Acadian Asset Management LLC boosted its position in Calithera Biosciences by 1,279.5% during the 4th quarter. Acadian Asset Management LLC now owns 21,686 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 20,114 shares during the period. Finally, Ellington Management Group LLC acquired a new position in Calithera Biosciences during the 4th quarter worth $191,000. Institutional investors and hedge funds own 68.37% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Leerink Swann Reiterates “Outperform” Rating for Calithera Biosciences (CALA)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/leerink-swann-reiterates-outperform-rating-for-calithera-biosciences-cala.html.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.